Recent Updates
Recently added Catalysts

125/ once-daily GSK573719/GW642444

Phase 3

Pulmonary Disease, Chronic Obstructive | Small molecule | Other |GSK plc|Last Updated: May 2, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment563
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01316887A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)PHASE3 COMPLETED 563Jan 1, 2011Jul 21, 2012May 2, 201854 United States, Chile +4
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Any On-treatment Adverse Event (AE) or Any Serious Adverse Event (SAE)
From the start of study drug up to 52 weeks

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. Medical or scientific judgment was to have been exercised in other important medical events. AEs with an onset on or after the date of the first dose of study drug and up to 1 day after the date of the last recorded dose of study drug were considered to be on-treatment AEs, Refer to the general AE/SAE module for a complete list of AEs and SAEs.

Secondary Endpoints
Number of Participants With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Over the Course of the 52-week Treatment Period
From the start of study drug up to 52 weeks
Time to the First On-treatment COPD Exacerbation
From the start of study drug up to 52 weeks
Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Creatine Kinase (CK), and Gamma Glutamyl Transferase (GGT) at Months 3, 6, 9, and 12
Baseline; Months 3, 6, 9, and 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeOTHER
Treatment Arms
ArmTypeDescription
GSK573719/GW642444EXPERIMENTAL125/25 mcg once-daily
GSK573719EXPERIMENTAL125 mcg once-daily
PlaceboPLACEBO_COMPARATORinactive
Interventions
NameTypeDescription
125/25 mcg once-daily GSK573719/GW642444DRUGGSK573719/GW642444
125mcg once-daily GSK573719DRUGGSK573719
Placebo once-dailyDRUGinactive
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 120 Years
SexALL
Healthy VolunteersNo
Study Sites54

Inclusion Criteria: * outpatient * signed and dated written informed consent * 40 years of age or older * male and female subjects * COPD diagnosis * at least 10 pack-year smoking history * post-albuterol/salbutamol FEV1/FVC ratio of \<0.70 and post-albuterol/salbutamol FEV1 greater than or equal t...

Countries:United StatesChileRomaniaRussiaSlovakiaSouth Africa
Unlock Eligibility Criteria